C1orf123_0610037L13Rik Inhibitors
Inhibitors of C1orf123_0610037L13Rik represent a diverse array of chemical compounds that exert their effects through intricate cellular pathways, ultimately converging to reduce the functional activity of this specific protein. Staurosporine, a broad kinase inhibitor, and LY 294002, a PI3K-specific inhibitor, both culminate in the suppression of kinase-driven signaling that is imperative for C1orf123_0610037L13Rik function. Such inhibition undermines the phosphorylation events necessary for C1orf123_0610037L13Rik's role within the cell, thereby attenuating its activity. Similarly, PD 98059 and U0126 target the MEK/ERK pathway, while SB 203580 impedes p38 MAP kinase signaling, both of which are critical to the modulation of processes that C1orf123_0610037L13Rik is posited to influence. By blocking these kinases, the inhibitors impede the signaling cascades that facilitate C1orf123_0610037L13Rik's participation in cellular functions. Bortezomib's proteasome inhibition further destabilizes the protein's regulatory environment, leading to an indirect decrease in its activity levels. Rapamycin, by inhibiting mTOR, and Wortmannin, through PI3K suppression, exert a downward pressure on C1orf123_0610037L13Rik's activity by curtailing the protein synthesis and growth signals that might otherwise enhance its functional presence.
Meanwhile, SP600125, as a JNK pathway inhibitor, and Triciribine, an Akt pathway antagonist, underscore the intricate interplay between signaling pathways and the functional state of C1orf123_0610037L13Rik. The inhibition of these pathways suggests a diminished capacity for C1orf123_0610037L13Rik to fulfill its cellular role, which may include but is not limited to apoptosis, differentiation, and cellular response mechanisms. Each inhibitor operates by meticulously unwinding the signaling threads that sustain C1orf123_0610037L13Rik's activity, culminating in a synergistic downregulation of its function. Collectively, these inhibitors elucidate a biochemical narrative marked by an extensive network of signaling pathways, where the modulation of one ripple cascades to impact the functionality of C1orf123_0610037L13Rik, a testament to the complex regulatory mechanisms that govern protein activity within the cellular milieu.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases, known to inhibit a wide range of kinases by competing with ATP binding sites. Inhibition of key kinases in signaling pathways that C1orf123_0610037L13Rik is involved with, like PI3K/Akt or MAPK, could indirectly diminish the protein's activity by disrupting the phosphorylation events necessary for its functional role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a specific inhibitor of the PI3K family, which plays a crucial role in the PI3K/Akt signaling pathway. By inhibiting PI3K, LY294002 prevents Akt phosphorylation and activation, leading to a downstream reduction in signaling events that C1orf123_0610037L13Rik may be involved in, therefore indirectly diminishing the protein's functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which is a part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK, a kinase that may regulate the functional activity of C1orf123_0610037L13Rik indirectly by phosphorylation. This inhibition may decrease the protein's ability to participate in its associated signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase, which may indirectly inhibit C1orf123_0610037L13Rik by blocking p38 MAPK-mediated signaling pathways. Since p38 MAPK is involved in response to stress stimuli and cellular signals, its inhibition could lead to diminished signaling through pathways where C1orf123_0610037L13Rik is a component, thereby reducing the protein's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly diminishes the activity of C1orf123_0610037L13Rik by impeding the mTOR signaling pathway. mTOR is a key regulator of cell growth and proliferation, and its inhibition can lead to a decrease in the functional processes in which C1orf123_0610037L13Rik may play a part, thus reducing the protein's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, Wortmannin can suppress the downstream Akt signaling pathway, which may be necessary for the proper function of C1orf123_0610037L13Rik. This suppression could result in a diminished functional role of C1orf123_0610037L13Rik within those cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal Kinase), part of the MAPK signaling pathway. Through inhibition of JNK, SP600125 can indirectly reduce the activity of C1orf123_0610037L13Rik if the protein is involved in pathways or processes regulated by JNK, such as apoptosis or cell differentiation, leading to diminished protein function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that could potentially influence the stability of C1orf123_0610037L13Rik by preventing the degradation of proteins that regulate its stability or localization. This could lead to an indirect downregulation of C1orf123_0610037L13Rik activity due to altered proteostasis and intracellular signaling equilibrium. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is a specific Akt inhibitor. By inhibiting Akt, it could potentially lead to the reduced activity of C1orf123_0610037L13Rik | ||||||